Current Issue
Displaying 6 results:
Free
Case report
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu
Antiviral Therapy 2020; 25:233-239
Free
Short communication
Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system
Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, Graham Sewell, Andrew Hughes, Heinz Feldmann
Antiviral Therapy 2020; 25:223-231
Original article
Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B
Boris JB Beudeker, Zwier MA Groothuismink, Robert A de Man, Harry LA Janssen, Annemiek A van der Eijk, Andre Boonstra, Milan J Sonneveld
Antiviral Therapy 2020; 25:217-222
Original article
Dynamics of HBV surface antigen related end points in chronic hepatitis B infection: a systematic review and meta-analysis
Yusi Chen, Justin Jinhui Li, Rong Chen, Gailing Li, Jia Ji
Antiviral Therapy 2020; 25:203-215
Original article
DAA-based treatment for HIV–HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study
Loredana Alessio, Lorenzo Onorato, Vincenzo Sangiovanni, Francesco Borrelli, Elio Manzillo, Vincenzo Esposito, Filomena Simeone, Salvatore Martini, Nicolina Capoluongo, Sebastiano Leone, Giovanni Di Filippo, Maurizio D’Abbraccio, Lucia Aprea, Angelo Salomone Megna, Eugenio Milano, Viviana Rizzo, Annalisa Saracino, Nicola Coppola
Antiviral Therapy 2020; 25:193-201
Review
The effects of nucleoside/nucleotide analogues on host immune cells: the baseline for future immune therapy for HBV?
Lauke L Boeijen, Michelle Spaan, André Boonstra
Antiviral Therapy 2020; 25:181-191